Related Experiment Video
Updated: May 7, 2026

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
Published on: March 11, 2014
Papillomavirus-associated squamous skin cancers following transplant immunosuppression: one Notch closer to control
Kate Connolly1, Pete Manders, Peter Earls
1Department of Oncology, St. Vincent's Hospital, The Kinghorn Cancer Centre, UNSW Clinical School, Sydney, Australia.
Abstract:
The frequent occurrence of cutaneous squamous cell carcinomas (SCCs) containing weakly tumorigenic human papillomaviruses (HPVs) following iatrogenic immunosuppression for organ transplantation remains incompletely understood. Here we address this problem in the light of recent insights into (1) the association of low-risk β-HPVs with skin SCCs in the rare genetic syndromes of epidermodysplasia verruciformis and xeroderma pigmentosum, (2) the frequent recovery of post-transplant tumor control on substituting calcineurin-inhibitory with mTOR-inhibitory immunosuppression, (3) the unexpectedly favorable prognosis of node-positive SCCs containing high-risk α-HPVs originating in the activated immune niche of the oropharynx, (4) the rapid occurrence of HPV-negative SCCs in ultraviolet (UV)-damaged skin of melanoma patients receiving Raf-inhibitory drugs, and (5) the selective ability of β-HPV E6 oncoproteins to inhibit Notch tumor-suppressive signaling in cutaneous and mesenchymal tissues. The crosstalk so implied between oncogenic UV-induced mutations, defective host immunity, and β-HPV-dependent stromal-epithelial signaling suggests that immunosuppressants such as calcineurin inhibitors intensify mitogenic signalling in TP53-mutant keratinocytes while also abrogating immune-dependent Notch-mediated tumor repression. This emerging interplay between solar damage, viral homeostasis and immune control makes it timely to reappraise strategies for managing skin SCCs in transplant patients.
Insights
Transplant patients frequently develop skin squamous cell carcinomas (SCCs) with human papillomaviruses (HPVs). Immunosuppression, UV damage, and HPV signaling interplay to drive SCC development, necessitating strategy reappraisal.
Area of Science:
- Dermatology
- Oncology
- Virology
Background:
- Cutaneous squamous cell carcinomas (SCCs) are common in organ transplant recipients, often associated with human papillomaviruses (HPVs).
- The precise mechanisms linking immunosuppression, HPV, and SCC development remain incompletely understood.
- Recent findings illuminate the roles of specific HPV types, genetic syndromes, and therapeutic interventions in SCC pathogenesis.
Purpose of the Study:
- To elucidate the complex interplay between iatrogenic immunosuppression, human papillomaviruses (HPVs), and the development of cutaneous squamous cell carcinomas (SCCs).
- To integrate recent insights into HPV associations, immunosuppressive drug effects, and tumor microenvironment signaling in SCC pathogenesis.
- To inform reappraisal of management strategies for skin SCCs in transplant patients.
Main Methods:
- Review and synthesis of recent findings on HPV-beta (β) and HPV-alpha (α) types in SCCs.
- Analysis of the impact of immunosuppressive agents (calcineurin inhibitors, mTOR inhibitors) on tumor control.
- Investigation of the role of UV radiation, TP53 mutations, and Notch signaling in SCC development.
Main Results:
- Low-risk β-HPVs are associated with SCCs in genetic syndromes; high-risk α-HPVs in oropharyngeal SCCs have a favorable prognosis.
- Substitution of calcineurin inhibitors with mTOR inhibitors often improves post-transplant tumor control.
- β-HPV E6 oncoproteins inhibit Notch signaling, potentially exacerbating SCC development in conjunction with UV damage and immunosuppression.
Conclusions:
- A complex interplay exists between UV-induced mutations, impaired immunity, and β-HPV-driven signaling in skin SCCs.
- Calcineurin inhibitors may intensify mitogenic signaling in TP53-mutant keratinocytes and reduce immune-mediated tumor repression.
- Reappraising management strategies for skin SCCs in transplant patients is timely given these insights.
More Related Videos
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
07:43Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples
Published on: July 29, 2017
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Mechanisms of Retrovirus-induced Cancers
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Tumor Immunotherapy
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...